SCHEMBL13571406

SCHEMBL13571406

O=C(Nc1nnc(-c2ccco2)o1)c1cncc(-c2ccc(-c3ccccc3)cc2)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.62
▸ KDM4E B2RXH2 6/20 0.62
▸ RAB9A P51151 3/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ ALOX12 P18054 2/20 0.59
▸ NPC1 O15118 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ STAT3 P40763 2/20 0.57
▸ HTT P42858 3/20 0.57
▸ MAPK1 P28482 1/20 0.55
▸ LCLAT1 Q6UWP7 1/20 0.55
▸ MEN1 O00255 1/20 0.54
▸ ADCY8 P40145 2/20 0.53
▸ ADCY1 Q08828 2/20 0.53
▸ KDM4A O75164 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ KDM4C Q9H3R0 1/20 0.53
▸ ALDH1A1 P00352 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13571160 0.89 LMNA (0.57) LMNAKDM4ERAB9ASMN1; SMN2ALOX12
SCHEMBL13570971 0.88 LMNA (0.72) LMNAKDM4ERAB9ASMN1; SMN2ALOX12
SCHEMBL13571330 0.88 LMNA (0.72) LMNAKDM4ERAB9ASMN1; SMN2ALOX12
SCHEMBL17716948 0.88 KDM4E (0.76) LMNAKDM4ERAB9ASMN1; SMN2ALOX12
SCHEMBL13571357 0.87 LMNA (0.71) LMNAKDM4ERAB9ASMN1; SMN2ALOX12
SCHEMBL12490865 0.87 LMNA (0.73) LMNAKDM4ERAB9ASMN1; SMN2ALOX12
SCHEMBL13570912 0.86 LMNA (0.72) LMNAKDM4ERAB9ASMN1; SMN2ALOX12
SCHEMBL13570785 0.84 LMNA (0.67) LMNAKDM4ERAB9ASMN1; SMN2ALOX12
SCHEMBL13571170 0.84 LMNA (0.67) LMNAKDM4ERAB9ASMN1; SMN2ALOX12
SCHEMBL13571012 0.84 LMNA (0.63) LMNAKDM4ERAB9ASMN1; SMN2ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796320-B2 1,3,4-Oxadiazole-2-carboxamide compound GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2014-08-05 — — US claimed
US-20120302524-A1 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2012-11-29 — — US claimed
EP-2520575-A1 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND General Incorporated Association Pharma Valley Project Supporting Organization (JP) 2012-11-07 — — EP claimed
EP-2520575-B1 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND GEN INC ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2016-11-30 — — EP disclosed
US-8796320-B2 1,3,4-Oxadiazole-2-carboxamide compound GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2014-08-05 — — US disclosed
US-20120302524-A1 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2012-11-29 — — US disclosed
EP-2520575-A1 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND General Incorporated Association Pharma Valley Project Supporting Organization (JP) 2012-11-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302524-A1 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND STAT3, JAK2, STAT5A LMNA 4594/4885KDM4E 480/4885RAB9A 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback